Application of fibrate drugs used as drugs for inhibiting myopia

A fibrate and drug technology, applied in the field of drug preparation, can solve the problems of unclear myopia, there is no effective preventive treatment for myopia and the like, and achieve the effect of inhibiting myopia

Inactive Publication Date: 2013-03-13
WENZHOU MEDICAL UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Since the mechanism of the development of myopia is still unclear, there

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of fibrate drugs used as drugs for inhibiting myopia
  • Application of fibrate drugs used as drugs for inhibiting myopia
  • Application of fibrate drugs used as drugs for inhibiting myopia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1: The experimental animal is a 3-week-old British tricolor short-haired guinea pig. Monocular form deprivation (FDM) was performed by mask method for 4 weeks, and clofibrate was given to the form deprived eye every day by peribulbar injection. Animals in form deprivation group were randomly divided into 3 groups: form deprivation group (FDM), form deprivation + vehicle control group (FDM + vehicle), form deprivation + drug group (FDM + 8ug / 100ul and 80ug / 100ul chlorine bebutyrate group). Drug injections were performed at 9 am every day for 4 consecutive weeks, and the fellow eye was left untreated. At the age of 3 (before the experiment), 5 weeks (treatment for 2 weeks), and 7 weeks (treatment for 4 weeks), the refraction was measured with an infrared eccentric photorefractor, the corneal curvature was measured with a keratometer, and the axial parameters were measured by A-ultrasound.

[0024] The results showed that the degree of elongation of the vitreous ...

Embodiment 2

[0029] Embodiment 2: other test conditions of embodiment 2 are the same as embodiment 1, and the injection drug is changed into fenofibrate, diagram 2-1 As shown, after 2 weeks of administration, the formation of myopia in the administration group was reduced compared with the solvent control group, and there was a significant difference in the amount of myopia formed after 4 weeks of administration. Figure 2-2 , 2-3 Respectively, after 4 weeks of administration, the vitreous cavity and eye axis extension of the administration group were significantly less than those of the solvent control group. Figure 2-4 It shows that there is no difference in corneal curvature between the administration group and the solvent control group every week after the medication, indicating that the drug has no effect on the corneal curvature. Therefore, fenofibrate can also effectively inhibit the formation of form deprivation myopia.

Embodiment 3

[0030] Embodiment 3: other test conditions of embodiment 3 are the same as embodiment 1, and the injection drug is changed into bezafibrate, Figure 3-1 As shown, after 2 weeks of administration, the formation of myopia in the administration group was reduced compared with the solvent control group, and there was a significant difference in the amount of myopia formed after 4 weeks of administration. 3-2 and 3-3 respectively show that after 4 weeks of administration, the extension of the vitreous cavity and eye axis of the administration group is significantly less than that of the solvent control group. Figure 3-4 It shows that there is no difference in corneal curvature between the administration group and the solvent control group every week after the medication, indicating that the drug has no effect on the corneal curvature. Therefore, bezafibrate can also effectively inhibit the formation of form deprivation myopia.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a method for preparing drugs capable of delaying and inhibiting myopia. The fibrate lipid-lowering drugs, such as Clofibrate, Fenofibrate and Bezafibrate, are used as the myopia drugs for treating myopia by inhibiting the formation of the myopia.

Description

technical field [0001] The invention relates to a preparation method of a medicine for delaying and inhibiting myopia, which utilizes the application of blood lipid-lowering medicines such as clofibrate, fenofibrate and bezafibrate in preparing the medicine for inhibiting myopia. Background technique [0002] Myopia is a disease with high global incidence. my country is one of the countries with the highest prevalence of myopia in the world, with as many as 500 million people suffering from it. Therefore, myopia is also known as China's "national disease". Epidemiological surveys show that myopia is currently the primary factor leading to low vision in my country, and pathological myopia is one of the main causes of blindness and low vision in my country. [0003] Because the mechanism of the occurrence and development of myopia is still unclear, so far there is no effective prevention and mechanistic treatment of myopia. Contents of the invention [0004] The object of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00A61K31/216A61K31/192A61P27/10
Inventor 周翔天瞿佳潘妙珍陈江帆
Owner WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap